SCHEMBL30838

SCHEMBL30838

C=CCP(=O)(O)S

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28687853 0.75
SCHEMBL360281 0.75
SCHEMBL30383 0.75
Ammonia Solution, Strong SCHEMBL2540910 0.73
Ammonia Solution, Strong SCHEMBL6676854 0.73 LPAR2 (0.33)
Phosphoric Acid SCHEMBL10534010 0.73 KDM4E (0.37)
Hydrochloric Acid SCHEMBL11081569 0.73 LPAR2 (0.33)
SCHEMBL2538056 0.73
SCHEMBL2543714 0.73
SCHEMBL2542186 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 7369 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023107896-A9 TREATMENT OF FGG RELATED DISEASES AND DISORDERS EMPIRICO INC. (US) 2024-07-11 WO claimed
WO-2024137663-A2 TREATMENT OF DKK2 RELATED DISEASES AND DISORDERS EMPIRICO INC. (US) 2024-06-27 WO claimed
WO-2024129886-A2 TREATMENT OF MST1 RELATED DISEASES AND DISORDERS EMPIRICO INC. (US) 2024-06-20 WO claimed
WO-2024118979-A1 TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS EMPIRICO INC. (US) 2024-06-06 WO claimed
US-20240175031-A1 TREATMENT OF MST1 RELATED DISEASES AND DISORDERS EMPIRICO INC. 2024-05-30 US claimed
EP-4359535-A1 TREATMENT OF DKK2 RELATED DISEASES AND DISORDERS EMPIRICO INC. (US) 2024-05-01 EP claimed
EP-4355878-A1 TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS EMPIRICO INC. (US) 2024-04-24 EP claimed
EP-4355355-A1 TREATMENT OF PLIN1 RELATED DISEASES AND DISORDERS EMPIRICO INC. (US) 2024-04-24 EP claimed
WO-2024077262-A2 METHODS AND COMPOSITIONS FOR SILENCING ELAVL2 EXPRESSION FOR THE TREATMENT OF DISEASE UNIVERSITY OF MASSACHUSETTS (US) 2024-04-11 WO claimed
US-20240093203-A1 SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2024-03-21 US claimed
EP-0652890-A1 OLIGONUCLEOTIDE ALKYLPHOSPHONOTHIOATES HYBRIDON, Inc. (US) 1995-05-17 EP claimed
WO-1995009236-A9 USING ANTISENSE OLIGONUCLEOTIDES TO MODULATE NERVE GROWTH AND TO REVERSE β/A4 AMYLOID-INDUCED MORPHOLOGY 1995-05-04 WO claimed
EP-0649467-A1 SELF-STABILIZED OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS HYBRIDON, Inc. (US) 1995-04-26 EP claimed
WO-1995009236-A1 USING ANTISENSE OLIGONUCLEOTIDES TO MODULATE NERVE GROWTH AND TO REVERSE β/A4 AMYLOID-INDUCED MORPHOLOGY THE GENERAL HOSPITAL CORPORATION (US) 1995-04-06 WO claimed
WO-1994023028-A2 MODIFIED OLIGONUCLEOTIDES HAVING IMPROVED ANTI-INFLUENZA ACTIVITY HYBRIDON, INC. (US) 1994-10-13 WO claimed
WO-1994017093-A1 OLIGONUCLEOTIDE ALKYLPHOSPHONATES AND ALKYLPHOSPHONOTHIOATES HYBRIDON, INC. (US) 1994-08-04 WO claimed
WO-1994015946-A1 SYNTHESIS OF DIMMER BLOCKS AND THEIR USE IN ASSEMBLING OLIGONUCLEOTIDES HYBRIDON, INC. (US) 1994-07-21 WO claimed
WO-1994002499-A1 OLIGONUCLEOTIDE ALKYLPHOSPHONOTHIOATES HYBRIDON, INC. (US) 1994-02-03 WO claimed
WO-1994001550-A1 SELF-STABILIZED OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS HYBRIDON, INC. (US) 1994-01-20 WO claimed
US-4354977-A STEROID CONJUGATES COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION (AU) 1982-10-19 US claimed